You are here

Universal Plasma Generator for Selective Removal of Anti-A and Anti-B Antibodies from Donor Plasma

Award Information
Agency: Department of Defense
Branch: Defense Health Agency
Contract: W81XWH-17-C-0080
Agency Tracking Number: H2-0203
Amount: $1,000,000.00
Phase: Phase II
Program: STTR
Solicitation Topic Code: DHP15B-001
Solicitation Number: 2015.0
Solicitation Year: 2015
Award Year: 2017
Award Start Date (Proposal Award Date): 2017-06-14
Award End Date (Contract End Date): 2019-12-13
Small Business Information
2501 Earl Rudder Freeway South
College Station, TX 77845
United States
DUNS: 184758308
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Dr. Ritwik Ghosh
 Chief Technologist
 (979) 764-2200
Business Contact
 Ms. Jennifer Rich
Phone: (979) 764-2200
Research Institution
 University of Pittsburgh
 Edward Michael Kastriba
 (412) 624-5238
 Nonprofit College or University

Traumatic injury accounts for 14.2% of all fatalities. Clinical management of trauma often requires massive plasma transfusions. However, in critical combat casualty care or in civilian emergency trauma care, plasma of compatible blood group may not be readily available. Transfusion with incompatible plasma may result in potentially fatal hemagglutination in the recipient. Typeless or universal plasma i.e. plasma without anti-A/B antibodies can be safely transfused into any recipient without risk of hemagglutination. Lynntech and its STTR consortium have demonstrated very strong proof-of-concept for a novel universal plasma generator device in the preceding Phase I effort. Our device has been shown to selectively remove only anti-A/B antibodies from actual human plasma samples without co-depleting coagulation factors or total protein, thus making the resultant universal plasma safe to transfuse into patients of any blood type. Our device can be integrated into existing plasmapheresis instruments and also function standalone to process fresh frozen plasma thereby fulfilling the critical need for always-on-hand typeless plasma for safe transfusions. This proposed Phase II aims to optimize our approach and demonstrate scaled up production of universal plasma with our device to considerably improve the TRL and position the technology for FDA clearance and commercialization in future phases.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government